Marstacimab for Hemophilia A and B: Mechanism of Action │PHARMACOLOGY

The FDA has approved marstacimab, for routine prophylaxis to prevent or reduce bleeding episodes, in adults and adolescents ages 12 years and older, with hemophilia A or B. This video explains how marstacimab works and key clinical trial results that led to its FDA approval. Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References: 1. Mehta P, Reddivari AKR. Hemophilia. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31869071. 2. https://www.fda.gov/news-events/press... 3. https://www.osmosis.org/answers/coagu... 4. Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024 Apr;30 Suppl 3:39-44. doi: 10.1111/hae.14976. Epub 2024 Mar 13. PMID: 38481077. 5. https://www.pfizer.com/news/press-rel... 6. https://touchhaematology.com/haemosta... 7. https://ash.confex.com/ash/2023/webpr... #marstacimab #Hympavzi #newtreatment #drugdiscovery #clinicaltrial #FDAapproval #hemophilia #bleedingdisorders #raredisease #medicaleducation #medicalscience